Real-world clinical experience of secukinumab in Chinese patients with psoriasis in real-world practice: a 36-week single-center study of 24 patients

Chin Med J (Engl). 2020 Dec 14;133(24):3020-3022. doi: 10.1097/CM9.0000000000001259.

Authors

Jing Zhang^{1

2}, Chao Ji^{1

2}, Bo Cheng^{1

2}, Shi-Fan Ruan^{1

2}, Tao Liu³, Jin-Wen Huang^{1

2}

Affiliations

¹ Department of Dermatology, Institute of Dermatology and Venereology, The First Affiliated Hospital of Fujian Medical University, Fuzhou, Fujian 350005, China.
² Key Laboratory of Skin Cancer of Fujian Higher Education Institutions, the First Affiliated Hospital, Fujian Medical University, Fuzhou, Fujian 350005, China.
³ Department of Medical Affairs, Beijing Novartis Pharma Company Limited, Shanghai 201203, China.

No abstract available

MeSH terms

Antibodies, Monoclonal, Humanized*
China
Double-Blind Method
Humans
Psoriasis* / drug therapy
Severity of Illness Index
Treatment Outcome

Substances

Antibodies, Monoclonal, Humanized
secukinumab